<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01050647</url>
  </required_header>
  <id_info>
    <org_study_id>SU-01082010-4683</org_study_id>
    <secondary_id>17976</secondary_id>
    <nct_id>NCT01050647</nct_id>
  </id_info>
  <brief_title>Progesterone for the Management of Preterm, Premature Rupture of the Membranes: A Randomized Controlled Trial.</brief_title>
  <official_title>Progesterone for the Management of Preterm, Premature Rupture of the Membranes: A Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preterm birth is the leading cause of neonatal death and a significant cause of life long
      disability and health problems. It has been shown that the drug 17-hydroxyprogesterone
      caproate can help reduce the risk of preterm delivery in women with certain risk factors for
      preterm birth. We hope to learn whether this same medication can be used to prolong pregnancy
      in a group of patients in whom this medication has not been previously studied. Specifically,
      we hope to learn whether progesterone supplementation will delay delivery in women with
      pre-term, premature rupture of membranes (PPROM).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      When women present to either the Obstetrical clinic or labor and delivery with a complaint of
      possible preterm, premature rupture of membranes (PPROM), they will be examined by an
      obstetrician to either confirm or rule out this diagnosis. If they are diagnosed with PPROM,
      they will then be admitted to Lucile Packard Children's Hospital and treated with the normal
      protocol which includes receiving antibiotics, receiving steroids, being hospitalized until
      delivery, and having ongoing maternal and fetal monitoring for possible complications. The
      patients will be identified by their treating obstetricians as possible study candidates and
      asked by a member of the treatment team if they are potentially interested in participating
      in a research study. Subsequently, a member of the study team or the treating physician will
      approach the patient about participating in the trial. Those who choose to participate will
      receive the standard care protocol in addition to receiving the study medication. The study
      medication will be a weekly injection of either placebo or 17-hydroxyprogesterone caproate or
      placebo. The placebo medication (castor oil) was chosen as it has been used in previous
      studies as a placebo for 17-hydroxyprogesterone caproate. The choice of which medication the
      patient receives will be determined by a randomization table. Only the pharmacist will be
      aware of the medication that has been administered. The patient, members of the treatment
      team, and members of the study team will be blinded to the medication that is being
      administered. The timing of their delivery will be managed by the treating obstetrician
      according to standard medical practice. After delivery, the patient's and her infant's
      medical outcomes will be recorded for analysis.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Achievement of 34 Weeks Gestation</measure>
    <time_frame>From enrollment until delivery, an average of 34 weeks</time_frame>
    <description>Delayed delivery until 34 weeks gestation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Neonatal Respiratory Distress Syndrome</measure>
    <time_frame>From delivery until neonatal hospital discharge, assessed up to 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Neonatal Grade III - IV Intraventricular Hemorrhage</measure>
    <time_frame>From delivery until neonatal hospital discharge, assessed up to 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Neonatal Necrotizing Enterocolitis</measure>
    <time_frame>From delivery to neonatal discharge, assessed up to 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Length of NICU and Total Hospital Stay Assessed as Number of Days</measure>
    <time_frame>From birth to discharge form delivery hospital, assessed up to 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Latency Assessed as Number of Days</measure>
    <time_frame>From rupture of membranes until delivery, assessed up to 34 weeks of gestation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Pregnancy Complications</condition>
  <arm_group>
    <arm_group_label>17-hydroxyprogesterone caproate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Weekly injections of 17-hydroxyprogesterone caproate until patient reached 34 completed weeks of gestation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Castor oil injections</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Weekly injections of Caster Oil (placebo)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>17-Hydroxyprogesterone Caproate</intervention_name>
    <description>Weekly injections of 17-hydroxyprogesterone caproate.</description>
    <arm_group_label>17-hydroxyprogesterone caproate</arm_group_label>
    <other_name>Active study drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Caster Oil injections</intervention_name>
    <description>Weekly injection of Caster Oil (Placebo) until patient reached 34 weeks gestation.</description>
    <arm_group_label>Castor oil injections</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18yr of age

          2. Singleton pregnancy

          3. PPROM confirmed on clinical exam

          4. GA between 24+0 and 33+5 wk

          5. Ability to understand consent in either English or Spanish

        Exclusion Criteria:

          1. Contraindication to ongoing pregnancy including:

               1. Evidence of active infection

               2. Evidence of significant placental abruption

               3. IUFD diagnosed at the time of P-PROM diagnosis

          2. Major fetal malformation

          3. Maternal allergy to progesterone or placebo drug components

          4. Current use of progesterone at the time of P-PROM

          5. Multiple Gestations

          6. Inability to understand consent in either English or Spanish
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yasser Y El-Sayed, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Santa Clara Valley Medical Center</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2010</study_first_submitted>
  <study_first_submitted_qc>January 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2010</study_first_posted>
  <results_first_submitted>February 13, 2018</results_first_submitted>
  <results_first_submitted_qc>March 16, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 17, 2018</results_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Yasser Yehia El-Sayed</investigator_full_name>
    <investigator_title>Professor of Obstetrics and Gynecology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rupture</mesh_term>
    <mesh_term>Pregnancy Complications</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>17-alpha-hydroxy-progesterone caproate</mesh_term>
    <mesh_term>11-hydroxyprogesterone</mesh_term>
    <mesh_term>Castor Oil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>17-hydroxyprogesterone Caproate</title>
          <description>Weekly injections of 17-hydroxyprogesterone caproate until patient reached 34 completed weeks of gestation
17-Hydroxyprogesterone Caproate: Weekly injections of 17-hydroxyprogesterone caproate.</description>
        </group>
        <group group_id="P2">
          <title>Castor Oil Injections</title>
          <description>Weekly injections of Caster Oil (placebo)
Caster Oil injections: Weekly injection of Caster Oil (Placebo) until patient reached 34 weeks gestation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>17-hydroxyprogesterone Caproate</title>
          <description>Weekly injections of 17-hydroxyprogesterone caproate until patient reached 34 completed weeks of gestation
17-Hydroxyprogesterone Caproate: Weekly injections of 17-hydroxyprogesterone caproate.</description>
        </group>
        <group group_id="B2">
          <title>Castor Oil Injections</title>
          <description>Weekly injections of Caster Oil (placebo)
Caster Oil injections: Weekly injection of Caster Oil (Placebo) until patient reached 34 weeks gestation.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.7" spread="1.9"/>
                    <measurement group_id="B2" value="31.7" spread="2.0"/>
                    <measurement group_id="B3" value="31.7" spread="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of prior preterm birth</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Achievement of 34 Weeks Gestation</title>
        <description>Delayed delivery until 34 weeks gestation.</description>
        <time_frame>From enrollment until delivery, an average of 34 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>17-hydroxyprogesterone Caproate</title>
            <description>Weekly injections of 17-hydroxyprogesterone caproate until patient reached 34 completed weeks of gestation
17-Hydroxyprogesterone Caproate: Weekly injections of 17-hydroxyprogesterone caproate.</description>
          </group>
          <group group_id="O2">
            <title>Castor Oil Injections</title>
            <description>Weekly injections of Caster Oil (placebo)
Caster Oil injections: Weekly injection of Caster Oil (Placebo) until patient reached 34 weeks gestation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Achievement of 34 Weeks Gestation</title>
          <description>Delayed delivery until 34 weeks gestation.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Neonatal Respiratory Distress Syndrome</title>
        <time_frame>From delivery until neonatal hospital discharge, assessed up to 2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>17-hydroxyprogesterone Caproate</title>
            <description>Weekly injections of 17-hydroxyprogesterone caproate until patient reached 34 completed weeks of gestation
17-Hydroxyprogesterone Caproate: Weekly injections of 17-hydroxyprogesterone caproate.</description>
          </group>
          <group group_id="O2">
            <title>Castor Oil Injections</title>
            <description>Weekly injections of Caster Oil (placebo)
Caster Oil injections: Weekly injection of Caster Oil (Placebo) until patient reached 34 weeks gestation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Neonatal Respiratory Distress Syndrome</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.31</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Neonatal Grade III - IV Intraventricular Hemorrhage</title>
        <time_frame>From delivery until neonatal hospital discharge, assessed up to 2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>17-hydroxyprogesterone Caproate</title>
            <description>Weekly injections of 17-hydroxyprogesterone caproate until patient reached 34 completed weeks of gestation
17-Hydroxyprogesterone Caproate: Weekly injections of 17-hydroxyprogesterone caproate.</description>
          </group>
          <group group_id="O2">
            <title>Castor Oil Injections</title>
            <description>Weekly injections of Caster Oil (placebo)
Caster Oil injections: Weekly injection of Caster Oil (Placebo) until patient reached 34 weeks gestation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Neonatal Grade III - IV Intraventricular Hemorrhage</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.99</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Neonatal Necrotizing Enterocolitis</title>
        <time_frame>From delivery to neonatal discharge, assessed up to 2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>17-hydroxyprogesterone Caproate</title>
            <description>Weekly injections of 17-hydroxyprogesterone caproate until patient reached 34 completed weeks of gestation
17-Hydroxyprogesterone Caproate: Weekly injections of 17-hydroxyprogesterone caproate.</description>
          </group>
          <group group_id="O2">
            <title>Castor Oil Injections</title>
            <description>Weekly injections of Caster Oil (placebo)
Caster Oil injections: Weekly injection of Caster Oil (Placebo) until patient reached 34 weeks gestation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Neonatal Necrotizing Enterocolitis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.59</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neonatal Length of NICU and Total Hospital Stay Assessed as Number of Days</title>
        <time_frame>From birth to discharge form delivery hospital, assessed up to 2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>17-hydroxyprogesterone Caproate</title>
            <description>Weekly injections of 17-hydroxyprogesterone caproate until patient reached 34 completed weeks of gestation
17-Hydroxyprogesterone Caproate: Weekly injections of 17-hydroxyprogesterone caproate.</description>
          </group>
          <group group_id="O2">
            <title>Castor Oil Injections</title>
            <description>Weekly injections of Caster Oil (placebo)
Caster Oil injections: Weekly injection of Caster Oil (Placebo) until patient reached 34 weeks gestation.</description>
          </group>
        </group_list>
        <measure>
          <title>Neonatal Length of NICU and Total Hospital Stay Assessed as Number of Days</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" lower_limit="13" upper_limit="59"/>
                    <measurement group_id="O2" value="50" lower_limit="34" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.16</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Latency Assessed as Number of Days</title>
        <time_frame>From rupture of membranes until delivery, assessed up to 34 weeks of gestation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>17-hydroxyprogesterone Caproate</title>
            <description>Weekly injections of 17-hydroxyprogesterone caproate until patient reached 34 completed weeks of gestation
17-Hydroxyprogesterone Caproate: Weekly injections of 17-hydroxyprogesterone caproate.</description>
          </group>
          <group group_id="O2">
            <title>Castor Oil Injections</title>
            <description>Weekly injections of Caster Oil (placebo)
Caster Oil injections: Weekly injection of Caster Oil (Placebo) until patient reached 34 weeks gestation.</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Latency Assessed as Number of Days</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" lower_limit="8.9" upper_limit="29.1"/>
                    <measurement group_id="O2" value="8" lower_limit="5.3" upper_limit="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.14</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From enrollment up to discharge from the delivery hospital, assessed up to 2 months after delivery</time_frame>
      <group_list>
        <group group_id="E1">
          <title>17-hydroxyprogesterone Caproate</title>
          <description>Weekly injections of 17-hydroxyprogesterone caproate until patient reached 34 completed weeks of gestation
17-Hydroxyprogesterone Caproate: Weekly injections of 17-hydroxyprogesterone caproate.</description>
        </group>
        <group group_id="E2">
          <title>Castor Oil Injections</title>
          <description>Weekly injections of Caster Oil (placebo)
Caster Oil injections: Weekly injection of Caster Oil (Placebo) until patient reached 34 weeks gestation.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Anna Girsen</name_or_title>
      <organization>Stanford University</organization>
      <phone>6507255720</phone>
      <email>agirsen@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

